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Abstract
Background Edoxaban, an oral direct factor Xa inhibitor,
is in development for thromboprophylaxis, including pre-
vention of stroke and systemic embolism in patients with
atrial fibrillation (AF). P-glycoprotein (P-gp), an efflux
transporter, modulates absorption and excretion of xeno-
biotics. Edoxaban is a P-gp substrate, and several cardio-
vascular (CV) drugs have the potential to inhibit P-gp and
increase drug exposure.
Objective To assess the potential pharmacokinetic inter-
actions of edoxaban and 6 cardiovascular drugs used in the
management of AF and known P-gp substrates/inhibitors.
Methods Drug-drug interaction studies with edoxaban
and CV drugs with known P-gp substrate/inhibitor poten-
tial were conducted in healthy subjects. In 4 crossover,
2-period, 2-treatment studies, subjects received edoxaban
60 mg alone and coadministered with quinidine 300 mg
(n = 42), verapamil 240 mg (n = 34), atorvastatin 80 mg
(n = 32), or dronedarone 400 mg (n = 34). Additionally,
edoxaban 60 mg alone and coadministered with amioda-
rone 400 mg (n = 30) or digoxin 0.25 mg (n = 48) was
evaluated in a single-sequence study and 2-cohort study,
respectively.
Results Edoxaban exposure measured as area under the
curve increased for concomitant administration of edox-
aban with quinidine (76.7 %), verapamil (52.7 %), amio-
darone (39.8 %), and dronedarone (84.5 %), and exposure
measured as 24-h concentrations for quinidine (11.8 %),
verapamil (29.1 %), and dronedarone (157.6 %) also
increased. Administration of edoxaban with amiodarone
decreased the 24-h concentration for edoxaban by 25.7 %.
Concomitant administration with digoxin or atorvastatin
had minimal effects on edoxaban exposure.
Conclusion Coadministration of the P-gp inhibitors
quinidine, verapamil, and dronedarone increased edoxaban
exposure. Modest/minimal effects were observed for ami-
odarone, atorvastatin, and digoxin.
1 Introduction
Edoxaban is a novel, oral anticoagulant that inhibits factor
Xa (FXa), which is located at the confluence of the intrinsic
and extrinsic coagulation pathways, the primary site of
amplification in the coagulation cascade [1]. Edoxaban
binds to both free FXa and FXa within the prothrombinase
complex, therefore producing a dose-dependent decrease in
thrombin generation [2]. Edoxaban has recently been
approved in Japan for prophylaxis against deep vein
thrombosis in patients following hip and knee replacement
surgery [3]. In addition, ongoing phase 3 trials are
assessing the efficacy and safety of edoxaban for the
treatment and prevention of recurrences of venous throm-
boembolism (Hokusai-VTE [4]) and prevention of stroke
and systemic embolic events in patients with atrial fibril-
lation (ENGAGE-AF TIMI 48 [5]). The Hokusai-VTE trial
is evaluating edoxaban 60 mg once daily, while the
ENGAGE-AF trial is evaluating edoxaban 60 and 30 mg
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once daily [4, 5]. Edoxaban 60 and 30 mg once-daily doses
were selected for ENGAGE-AF based upon a phase 2 dose-
finding study in atrial fibrillation (AF) patients that showed
that these 2 dosing regimens provided similar or less fre-
quent bleeding than standard warfarin therapy [6].
The pharmacokinetics (PK) of edoxaban have been
extensively studied in healthy volunteers. Edoxaban is
rapidly absorbed with peak concentrations observed at
1–2 h postdose and elimination is biphasic with a mean
terminal elimination half-life (t) of 8.75–10.4 h [7].
Edoxaban is primarily eliminated unchanged through
multiple pathways, with approximately 50 % of systemi-
cally absorbed drug eliminated via renal excretion. The
most abundant metabolites (M4 and M1) are formed
through hydrolysis with minor contribution from cyto-
chrome P450 (CYP) 3A [8].
P-glycoprotein (P-gp) is an efflux transporter primarily
expressed in the apical/luminal membrane of epithelia of the
small intestine, hepatocytes, renal proximal tubules, and
other sites. With broad substrate specificity and high trans-
port capacity, P-gp can limit the systemic exposure of vari-
ous xenobiotics by decreasing intestinal absorption and
increasing renal excretion and biliary excretion [9–11].
Strong P-gp inhibitors may increase systemic absorption and
decrease elimination of P-gp substrates, resulting in increased
exposure. The US Food and Drug Administration (FDA)
now recommends that all investigational drugs should be
evaluated for effect on potential P-gp activity [12]. Results
from transporter studies using Caco-2 cells and wild-type
versus P-gp knockout mice indicate that edoxaban is a sub-
strate for P-gp, but not for other commonly tested uptake
transporters (eg, the organic anion transporter 1) [13].
Modeling and simulation analyses, which include AF
patients from a phase 2 dose-finding study, have demon-
strated that concomitant edoxaban and strong P-gp inhibitors
increase edoxaban exposure and the risk of bleeding [14].
Therefore, it is important to assess the effect of P-gp inhi-
bition on edoxaban PK by drugs that would be commonly co-
prescribed in the AF population. The objectives of the 6
studies described here were to evaluate potential PK inter-
actions between edoxaban and cardiovascular drugs that are
known P-gp substrates (digoxin, atorvastatin, quinidine, and
verapamil) and/or inhibitors (quinidine, digoxin, amiodarone,
dronedarone, verapamil, and atorvastatin) and which may be
prescribed to patients with AF [11, 15–18].
2 Methods
2.1 Study Designs
The design of the quinidine, verapamil, atorvastatin, and
dronedarone studies were based on standard drug-drug
interaction designs using 2-period, 2-treatment crossover
designs and taking into consideration the disposition of
edoxaban and the interacting drug [12]. Given amioda-
rone’s 58-day terminal elimination half-life (t1/2) [19], a
single-sequence design was selected to prevent carryover.
The study with digoxin used a dual-sequence, parallel
design [20]. Sample sizes were based on results from
previous PK studies of edoxaban and variability of edox-
aban PK parameters (eg, Ogata et al. [7]). The dose of
edoxaban was 60 mg, the highest dose being tested in
phase 3 clinical studies. The highest recommended thera-
peutic doses were employed for all potentially interacting
drugs. Studies were conducted at Celerion clinical research
units in Neptune, NJ (quinidine, digoxin, amiodarone,
verapamil, dronedarone), or Belfast, Northern Ireland, UK
(atorvastatin). An institutional review board approved all
protocols and each subject signed an informed consent
prior to study entry. The studies were conducted in
accordance with the international conference harmonisa-
tion guideline E6 for good clinical practice.
2.1.1 Quinidine
This was an open-label, randomized, 2-period, 2-treatment
crossover study in 42 healthy volunteers. Subjects were
randomized to receive 1 of 2 treatment regimens during the
first period, followed by a washout of 7–10 days before the
alternate treatment was administered during the second
period. The treatments were a single, oral dose of quinidine
300 mg (Mutual Pharmaceutical Co.) on day 1, quinidine
300 mg three times daily on days 2–3, and a single dose of
quinidine 300 mg on day 4, plus a single dose of edoxaban
60 mg on day 3; or edoxaban 60 mg once daily on days
1–4 and a single dose of quinidine 300 mg on day 3.
2.1.2 Digoxin
This was an open-label, dual-treatment sequence, parallel
study in 48 healthy subjects assigned to digoxin (Lanoxin,
GlaxoSmithKline) on days 1–7 (0.25 mg every 12 h on
days 1–2, then 0.25 mg once daily on days 3–7) followed
by coadministration of digoxin 0.25 mg once daily with
edoxaban 60 mg once daily on days 8–14; or edoxaban
60 mg once daily on days 1–7 followed by coadministra-
tion of edoxaban 60 mg daily with digoxin on days 8–14
(0.25 mg every 12 h on days 8–9, then 0.25 mg once daily
on days 10–14) [20].
2.1.3 Amiodarone
This was an open-label, single-sequence study in 30 heal-
thy volunteers. Subjects received 2 treatments in a fixed
sequence: (1) a single, oral dose of edoxaban 60 mg on day
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1, then (2) amiodarone 400 mg (Pacerone, Upsher-Smith
Laboratories, Inc.) once daily for 4 days (days 4–7) plus a
single oral dose of edoxaban 60 mg on day 7. There was a
3-day washout period between the 2 treatments.
2.1.4 Verapamil
This was an open-label, randomized, 2-period, 2-treatment
crossover study in 34 healthy volunteers. Subjects were
randomized to receive one of either 2 treatment regimens
during the first period, followed by a washout of at least
7 days before the alternate treatment was administered
during the second period. The treatments were verapamil
240 mg sustained-release (Calan SR, Pfizer Inc.) once daily
on days 1–11 and edoxaban 60 mg on day 10; or edoxaban
60 mg once daily on days 1–4 and verapamil 240 mg
sustained-release on day 3.
2.1.5 Atorvastatin
This was an open-label, randomized, 2-period, 2-treat-
ment crossover study in 32 healthy volunteers. Subjects
were randomized to receive one of either 2 treatment
regimens during the first period, followed by a washout
of at least 7 days before the alternate treatment was
administered during the second period. The treatments
were atorvastatin 80 mg (Lipitor, Pfizer) once daily on
days 1–8 plus edoxaban 60 mg on day 7; or edoxaban
60 mg on day 1.
2.1.6 Dronedarone
This was an open-label, randomized, 2-period, 2-treatment
crossover study in 34 healthy volunteers. Subjects were
randomized to receive one of either 2 treatment regimens
during the first period, followed by a washout of at least
7 days before the alternate treatment was administered
during the second period. The treatments were edoxaban
60 mg on day 1 under fed conditions; or dronedarone
400 mg (Multaq, Sanofi) twice daily on days 1–7 under fed
conditions plus edoxaban 60 mg on day 5 under fed
conditions.
2.2 Blood Sampling and Analysis for Edoxaban
Blood samples were collected to determine plasma edox-
aban concentrations at serial time points over 24 h (quin-
idine, digoxin, and verapamil) or 72 h (amiodarone,
atorvastatin, and dronedarone) after administration of
edoxaban. Plasma edoxaban concentrations were measured
by a validated liquid chromatography tandem mass spec-
trometry (LC-MS/MS) method with calibration ranges of
0.764 to 382 ng/mL (Advion BioServices, Ithaca, NY) for
all studies except for the digoxin study, which had a lower
limit of quantitation of 1 ng/mL.
Blood samples were also collected to confirm exposure
for the potentially interacting drugs. Validated LC-MS/MS
methods were used to quantify plasma drug concentrations
(quinidine and atorvastatin at PPD, Richmond, VA; ami-
odarone at Bioanalytical Systems, Inc, West Lafayette, IN;
verapamil and dronedarone at Celerion, Lincoln, NE).
Digoxin was analyzed by PPD using a validated radioim-
munoassay procedure.
2.3 Clinical Laboratory Assessments
Samples for routine laboratory testing were collected and
tested by a Clinical Laboratory Improvement Amend-
ments-approved laboratory. Results of hematology, serum
chemistry, coagulation, urinalysis, and fecal occult blood
(FOB) testing were classified according to the clinical
laboratory reference ranges.
2.4 Pharmacokinetic and Statistical Analyses
Pharmacokinetic parameters calculated from the individual
plasma concentrations included area under the plasma
concentration versus time curve (AUC) from time 0 to the
last measurable concentration or to 24 h (AUClast or
AUC0–24); AUC from the time of dosing extrapolated to
infinity, calculated as (AUC0–inf); maximum observed
plasma drug concentration (Cmax); time of maximum
observed concentration (tmax); terminal t1/2, calculated as
ln(2)/kz; and mean concentrations 24 h postdose (C24). All
PK parameters were calculated using WinNonlin Profes-
sional version 5.2 (Pharsight Corp., Mountain View, CA)
or version 4.0 (digoxin study only). Edoxaban PK param-
eters and plasma concentrations were summarized using
descriptive statistics.
The PK parameters for the interacting drugs were cal-
culated when possible and summarized along with the
plasma drug concentrations. All statistical summaries and
analyses were performed using SAS version 8.2 (SAS
Institute Inc., Cary, NC) or version 9.1.3 (dronedarone
study only).
Comparisons of the PK of edoxaban administered with a
potentially interacting drug versus edoxaban alone were
performed using an analysis of variance (ANOVA) model
with sequence, treatment, and period as fixed effects, and
subject nested within sequence as a random effect. The
ratios of the geometric least squares means (LSM) for the
ln-transformed parameters Cmax, AUClast, and/or AUC0–inf
were calculated for edoxaban alone versus edoxaban
administered with the interacting drug. The 90 % confi-
dence intervals (CI) of ratios were also calculated. If the
90 % CI was within the 80 to 125 % bioequivalence limit,
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it was concluded that there was no significant interaction
between edoxaban and the coadministered drug.
2.5 Safety
Safety endpoints included vital signs, electrocardiograms




In all, 220 subjects were enrolled in these studies. Demo-
graphic and baseline characteristics (Table 1) were similar
across studies; most subjects were predominantly African
American males with an approximate mean age of 30 years,
with the exception of the study with atorvastatin, conducted
in Belfast, Northern Ireland, UK, in which subjects were
slightly younger (mean age 24 years) and predominantly
white. At least 88 % of the subjects completed their studies
with the exception of the quinidine study, where only 29 of
the 42 randomized subjects completed the study (69 %): 2
were withdrawn due to protocol violations, 6 discontinued
due to AEs, and 5 withdrew consent.
3.2 Pharmacokinetics
3.2.1 Edoxaban
Edoxaban administered alone resulted in a range of mean
[±standard deviation (SD)] Cmax values of 223.4 (±75.0)
to 295.6 (±83.6) ng/mL across the 6 studies, indicating
consistent exposure of edoxaban (Tables 2, 3). Mean
total exposure values for edoxaban alone expressed as
AUC0–inf ranged from mean (±SD) values of 1576.8
(±322.7) to 1965.5 (±420.9) ngh/mL, consistent across
study cohorts and with historical data [7, 21–23]. In the
studies with quinidine and verapamil, a 24-h collection
period allowed only AUC0–24 calculations, and the mean
values reported for these 2 studies showed similar
exposure (1449 and 1438 ngh/mL, respectively). Peak
edoxaban concentrations were observed within 1–3 h
postdose.
3.2.2 Quinidine Study
The PK parameters for edoxaban administered with and
without quinidine are presented in Table 2. The geometric
LSM ratio values for AUC0-24 and Cmax of edoxaban plus
quinidine versus edoxaban alone were 176.7 % (90 % CI,
165.0–189.2) and 185.4 % (90 % CI, 164.8–208.5),
respectively (Fig. 1); increases of 76.7 and 85.4 %,
respectively. Coadministration of quinidine increased the
24-h concentration by 11.8 % (Fig. 2), and the rate of
edoxaban absorption was not affected by quinidine (med-
ian tmax = 1.48 h for edoxaban alone and 1.50 h for
edoxaban plus quinidine). The mean terminal elimination
t1/2 values were 6.43 and 4.97 h for edoxaban alone and
when administered with quinidine, respectively.
3.2.3 Digoxin Study
The geometric LSM ratio values for AUC0–s and Cmax of
edoxaban plus digoxin versus edoxaban alone were
Table 1 Demographic and baseline characteristics
Quinidine Digoxin Amiodarone Verapamil Atorvastatin Dronedarone
Enrolled 42 48 30 34 32 34
Completed 29 46 28 30 29 31
Sex [N (%)]
Male 35 (83.3) 45 (93.8) 26 (86.7) 28 (82.4) 22 (68.8) 34 (100)
Female 7 (16.7) 3 (6.3) 4 (13.3) 6 (17.6) 10 (31.3) 0
Race [N (%)]
American Indian/Alaskan Native 1 (2.4) 1 (2.1) 0 0 0 0
Asian 1 (2.4) 1 (2.1) 1 (3.3) 0 0 0
Black/African American 26 (61.9) 32 (66.7) 18 (60.0) 31 (91.2) 1 (3.1) 25 (73.5)
Native Hawaiian/Pacific Islander 0 1 (2.1) 1 (3.3) 0 0 1 (2.9)
Other 2 (4.8) 0 0 0 0 1 (2.9)
White 13 (31.0) 13 (27.1) 10 (33.3) 3 (8.8) 31 (96.9) 7 (20.6)
Age, years [mean (SD)] 30.9 (7.5) 31.1 (7.4) 32.2 (6.4) 31.4 (8.3) 24.4 (4.7) 29.9 (6.7)
Weight, kg [mean (SD)] 79.7 (12.0) 78.7 (11.7) 81.7 (11.3) 79.0 (12.8) 72.0 (11.9) 83.2 (9.1)
SD standard deviation
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109.5 % (90 % CI, 102.0–117.5) and 115.6 % (90 % CI,
102.8–130.0), respectively (Fig. 1); increases of 9.5 and
15.6 %, respectively [20]. Coadministration of digoxin
decreased the 24-h edoxaban concentration by 9.4 %
(Fig. 2). Similar rates of absorption, determined by median
tmax values (1.00 and 1.50 hours, respectively) and terminal
elimination t1/2 values (9.83 and 8.35 h, respectively), were
observed for edoxaban alone and edoxaban plus digoxin
(Table 2) [20].
3.2.4 Amiodarone Study
The PK parameters for edoxaban with and without amio-
darone are listed in Table 2. The geometric LSM ratio
values for AUC0–inf and Cmax of edoxaban plus amiodarone
versus edoxaban alone were 139.8 % (90 % CI,
134.1–145.7) and 166.0 % (90 % CI, 146.3–188.4),
respectively (Fig. 1); increases of 39.8 and 66.0 %,
respectively. Coadministration of amiodarone reduced the
Table 2 Pharmacokinetic parameters for edoxaban
Variable Quinidine 300 mg Digoxin 0.25 mg Amiodarone 400 mg
Edoxaban Edoxaban ? Quinidine Edoxaban Edoxaban ? Digoxin Edoxaban Edoxaban ? Amiodarone
Cmax (ng/mL) 223.4 (75.0) 390.4 (93.4) 250.0 (75.7) 296.2 (105.6) 251.3 (100.8) 401.6 (109.3)
C24 (ng/mL) 11.0 (4.4) 12.3 (4.3) 24.5 22.2 11.3 (5.5) 8.4 (3.2)
tmax (h) 1.48 (0.50–6.00) 1.50 (0.48–2.50) 1.00 (0.98–2.00) 1.50 (0.98–2.00) 1.25 (0.50–3.00) 1.50 (0.98–4.00)
AUC0–24
(ngh/mL)
1449.2 (328.6) 2485.3 (402.5) – – – –
AUClast
(ngh/mL)
1443.4 (329.7) 2484.4 (402.4) – – 1718.1 (351.6) 2415.6 (419.0)
AUC0–inf
(ngh/mL)
1576.8 (322.7) 2575.3 (414.1) – – 1743.1 (354.2) 2431.5 (418.7)
AUC0–s
(ngh/mL)
– – 1963.1 (353.8) 2167.0 (478.2) – –
t1/2 (h) 6.43
a (1.59) 4.97a (0.62) 9.83a (3.98) 8.35a (4.23) 12.25b (5.03) 10.81b (4.84)
All values are mean (SD) except tmax, which is median (minimum–maximum)
AUC area under the curve, Cmax maximum plasma concentration, C24 plasma concentration at 24 h postdose, SD standard deviation, tmax time to Cmax, t1/2
terminal half-life
a Serial measurements to 24 h
b Serial measurements to 72 h
Table 3 Pharmacokinetic parameters for edoxaban
Variable Verapamil 240 mg SR Atorvastatin 80 mg Dronedarone 400 mg
Edoxaban Edoxaban ? Verapamil Edoxaban Edoxaban ? Atorvastatin Edoxaban Edoxaban ? Dronedarone
Cmax
(ng/mL)
226.1 (104.9) 319.7 (95.7) 282.2 (88.6) 244.2 (87.3) 295.6 (83.6) 422.4 (70.4)
C24
(ng/mL)
11.0 (4.0) 14.2 (7.1) 12.6 (5.1) 13.6 (4.8) 5.9 (2.0) 15.2 (6.0)
tmax (h) 1.48 (0.52–2.98) 1.00 (0.48–2.98) 1.02 (0.48–5.98) 1.50 (0.48–3.00) 1.98 (0.50–4.03) 2.03 (1.00–4.00)
AUC0–24
(ngh/mL)
1438 (416.7) 2105 (372.3) – – – –
AUClast
(ngh/mL)
– – – – 1659.5 (310.8) 3007.4 (604.5)
AUC0–inf
(ngh/mL)
– – 1965.5 (420.9) 1983.0 (351.4) 1682.5 (313.8) 3070.7 (565.5)
t1/2 (h) 7.43
a (2.33) 6.79a (1.99) 12.02b (3.46) 12.77b (3.12) 10.2b (6.78) 12.8b (6.23)
All values are mean (SD) except tmax, which is median (minimum–maximum)
AUC area under the curve, Cmax maximum plasma concentration, C24 plasma concentration at 24 h postdose, SD standard deviation, tmax time to Cmax, t1/2
terminal half-life
a Serial measurements to 24 h
b Serial measurements to 72 h
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24-h edoxaban concentration by 25.7 % (Fig. 2). The
median tmax values were 1.25 h with edoxaban alone and
1.50 h with concomitant amiodarone. The mean terminal
elimination t1/2 values for edoxaban administered alone and
with amiodarone were 12.25 and 10.81 h, respectively.
3.2.5 Verapamil Study
The PK parameters for edoxaban administered with and
without verapamil are presented in Table 3. The geometric
LSM ratios for AUC0–24 and Cmax of edoxaban plus
verapamil versus edoxaban alone were 152.7 % (90 % CI,
140.9–165.4) and 153.3 % (90 % CI, 133.7–175.8)
respectively (Fig. 1); increases of 52.7 and 53.3 %,
respectively. Coadministration of verapamil increased the
24-h edoxaban concentration by 29.1 % (Fig. 2). The
median tmax values were 1.48 h for edoxaban alone and
1.00 h for edoxaban plus verapamil. Similar terminal
elimination t1/2 values were also observed for edoxaban
alone (7.43 h) and edoxaban plus verapamil (6.79 h).
Fig. 1 Ratios of Cmax and
AUC for edoxaban with and
without interacting drug.
Geometric least squares means.
AUC0–inf for amiodarone,
atorvastatin, and dronedarone;
AUC0–24 for quinidine and
verapamil; AUC0–s for digoxin.
Reference indicates edoxaban
Fig. 2 Ratios of C24 (plasma
concentration at 24 h postdose)
for edoxaban with and without
interacting drug. Arithmetic
means. Test indicates edoxaban
plus interacting drug; reference,
edoxaban
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3.2.6 Atorvastatin Study
The PK parameters for edoxaban administered with and
without atorvastatin are presented in Table 3. The geo-
metric LSM ratio values for AUC0–inf and Cmax of edox-
aban plus atorvastatin versus edoxaban alone were 101.7 %
(90 % CI, 95.7–108.1) and 85.8 % (90 % CI, 76.8–95.8),
respectively (Fig. 1); an increase of 1.7 % and a decrease
of 14.2 %, respectively. Coadministration of atorvastatin
increased the 24-h edoxaban concentration by 7.9 %
(Fig. 2). The median tmax values were 1.02 h for edoxaban
alone and 1.50 h for edoxaban plus atorvastatin. Similar
terminal elimination t1/2 values were also observed for
edoxaban alone (12.02 h) and edoxaban plus atorvastatin
(12.77 h).
3.2.7 Dronedarone Study
The PK parameters for edoxaban administered with and
without dronedarone are presented in Table 3. The geo-
metric LSM ratio values for AUC0–inf and Cmax of edox-
aban plus dronedarone versus edoxaban alone were
184.5 % (90 % CI, 177.9–191.4) and 145.8 % (90 % CI,
136.0–156.2), respectively (Fig. 1); increases of 84.5 and
45.8 %, respectively. Coadministration of dronedarone
increased the 24-h edoxaban concentration by 157.6 %
(Fig. 2). The median tmax values were 1.98 h for edoxaban
alone and 2.03 h for edoxaban plus dronedarone. Similar
terminal elimination t1/2 values were also observed for
edoxaban alone (10.2 h) and edoxaban plus dronedarone
(12.8 h).
3.3 Safety
Edoxaban was well tolerated when administered alone or
with either quinidine, digoxin, amiodarone, verapamil,
atorvastatin, or dronedarone. Table 4 summarizes the rates
of treatment-emergent AEs (TEAEs) for each study. There
were no deaths or serious AEs reported in these studies.
One subject was withdrawn from the amiodarone study due
to localized cellulitis. No subject withdrew prematurely
from the atorvastatin study. One subject was discontinued
prematurely from the digoxin study due to AEs that
included symptoms of chest discomfort and AV block was
noted on the ECG following digoxin treatment. Two sub-
jects discontinued prematurely from the dronedarone study
after elevated alanine aminotransferase levels were noted
during coadministration of dronedarone and edoxaban. A
total of 6 subjects were withdrawn from the quinidine study
due to AEs, which included 2 subjects with positive FOB, 1
subject who experienced QTc prolongation after quinidine
dosing, 1 subject with low hemoglobin, 1 subject with an
increase in creatine kinase, and 1 subject with headache
and nausea. Four subjects were withdrawn from the
verapamil study due to AEs, which included 1 subject with
positive FOB and 3 subjects with abnormal ECG following
verapamil monotherapy.
4 Discussion
These studies explored the drug-drug interactions between
edoxaban and 6 cardiovascular drugs that are likely to be
commonly co-prescribed with edoxaban in the AF patient
population and also have P-gp inhibition potential. These
drugs display differing degrees of P-gp inhibition, with
verapamil, quinidine, dronedarone, and amiodarone recog-
nized as strong P-gp inhibitors [12], while digoxin and
atorvastatin are recognized P-gp substrates [12, 16].
Coadministration of verapamil, quinidine, or dronedarone
resulted in [50 % increases in total exposure measured as
AUC and increases in the 24-h concentrations (a surrogate
for trough concentrations) of edoxaban. Edoxaban coad-
ministered with amiodarone increased total exposure by
\50 % and 24-h concentrations decreased by approxi-
mately 26 %. Coadministration of either digoxin or ator-
vastatin had relatively minor effects on the PK of edoxaban.
The 90 % CI for the geometric LSM ratio values for
AUC0–inf and Cmax of edoxaban were calculated per the
standard test statistics described in regulatory guidelines.
Salazar and colleagues used a pharmacometric model that
predicted the effect of edoxaban exposure on bleeding to
determine whether coadministration with these drugs
would result in clinically meaningful increases in edoxaban
exposure [14]. Pharmacometric analysis of a phase 2 study
in patients with AF determined that trough plasma con-
centrations were the most robust predictors of bleeding risk
[6]. Therefore, the observed edoxaban concentrations from
the drug-drug interaction studies were modeled to predict
trough concentrations at steady state. Increased exposure
resulting in bleeding greater than the established limit (ie,
greater than the observed warfarin bleeding) was consid-
ered clinically significant. On the basis of the results of the
pharmacometric analysis [14], verapamil, quinidine, and
dronedarone were determined to have the potential for
clinically meaningful effects on the disposition of edox-
aban. Therefore, a dose reduction of 50 % has been rec-
ommended for coadministration of edoxaban with
verapamil, quinidine, and dronedarone. The limited effects
of atorvastatin and digoxin on edoxaban PK may be due to
their weaker affinity for the P-gp transporter; therefore,
these drugs, at therapeutic doses, are not considered strong
P-gp inhibitors for edoxaban. Previous publications have
cited verapamil, quinidine, amiodarone, and dronedarone
as potent P-gp inhibitors based on the [25 % increase in
AUC of digoxin, considered a probe substrate for P-gp [12,
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16, 24–26]. Although amiodarone has been shown to have
strong P-gp inhibitory effects with other P-gp substrates,
the increased edoxaban exposure was modest. Based on the
pharmacometric analyses reported by Salazar et al. [14],
the increased edoxaban exposure associated with amioda-
rone did not result in significant bleeding based on these
model predictions and, therefore, no dose adjustment was
recommended.
The coadministration of these 6 cardiovascular drugs
with edoxaban was considered safe and well tolerated
within our study. There did not appear to be any significant
increases in TEAEs recorded during any coadministration,
and rates of TEAEs considered to be related to any study
drug were low. However, the studies assessed relatively
small numbers of healthy subjects and excluded those who
had recently received prescribed or over-the-counter sys-
temic or topical medications or herbal supplements. The
total observed bleeding events in these studies were rela-
tively minor in number and mild in severity; therefore, they
offer limited insight into the bleeding potential across these
dose regimens. With these caveats in mind, the incidence
of bleeding-related AEs did not portend any increased
bleeding when edoxaban was coadministered with one of
these specific cardiovascular medications, nor was there
any significant trend for increases in other AEs. However,
patients with AF tend to be elderly and have cardiovascular
comorbidities that may require treatment with one or more
additional medications. The AE profile for edoxaban
coadministered with these cardiovascular drugs will be
further evaluated in patients with AF or venous thrombo-
embolism in the large phase 3 ENGAGE AF-TIMI 48 [5]
and Hokusai-VTE [4] studies, respectively.
Total exposure of edoxaban with concomitant adminis-
tration of quinidine, verapamil, or dronedarone increased
\2-fold over the total exposure to edoxaban administered
alone. While the pharmacometric analyses of the interac-
tions between edoxaban and these 3 drugs suggest the
potential for increased bleeding risk [14], the magnitude of
these P-gp inhibitory effects was less than that which can
be observed with drug interactions involving other mech-
anisms such as drug metabolizing enzymes. For example,
statins that are extensively metabolized by CYP3A have
shown a 10-fold or more increase in blood levels when
coadministered with strong CYP3A inhibitors [12].
Therefore, the clinical relevance of the increases in expo-
sure to edoxaban when coadministered with quinidine,
verapamil, or dronedarone should be considered in the
context of the therapeutic index for edoxaban, particularly
for bleeding potential. The final determination of the rel-
ative effect of increased exposure on bleeding risk for
edoxaban administered concomitantly with verapamil,
quinidine, or dronedarone will be determined in the
ENGAGE AF-TIMI 48 and Hokusai-VTE trials.
Cardiologists should be aware of emerging data charac-
terizing the effect of the P-gp transport system on drug
exposure and its potential for drug-drug interactions, espe-
cially for cardiovascular drugs with narrow therapeutic
indices. While the potential for drug-drug interactions
attributed to drug metabolizing enzymes are relatively well
known, the results of these studies underscore the impor-
tance of drug-drug interactions involving P-gp. Potential
drug-drug interactions involving transporters were the focus
of a white paper published by the International Transporter
Consortium in 2010 [9] and also the recent release of the
FDA draft guidance on drug-drug interactions [12]. The
FDA guidance states that all investigational drugs should be
assessed using in vitro studies to determine the relative
affinity of the compound for the P-gp transporter. Trans-
porter assays measure the flux across various cell lines
overexpressing P-gp (eg, Caco-2 and MDRK), and the
relative flux (i.e.,[2) can be used to define whether a drug
is a P-gp substrate. The effect of P-gp on the disposition of
various compounds has also been assessed in P-gp knockout
mice relative to wild-type mice [27]. The FDA guidance
further states that P-gp substrates characterized by in vitro
assays as having significant potential for drug-drug inter-
actions should be investigated in clinical studies. Dose
administration guidance involving transporters should
continue to expand for newly approved drugs. The role of
the P-gp transporter system in various cardiovascular drugs
is the focus of a very recent article in the Journal of the
American College of Cardiology [28] and highlights the
importance of understanding P-gp interactions that may
occur between commonly co-prescribed drugs.
Our results suggest that quinidine, verapamil, and
dronedarone—cardiovascular drugs used to manage AF
patients that are likely to be prescribed with edoxaban—
present some potential risk of bleeding in these patients if
edoxaban is not dose-adjusted. Other recently developed
oral anticoagulants (dabigatran, rivaroxaban, and apixaban)
are also P-gp substrates [29–31]. Currently, in patients with
normal renal function, no dose adjustments are recom-
mended for patients who are also taking a P-gp inhibitor
along with dabigatran or rivaroxaban [29, 30]. A dose
adjustment is recommended for patients with moderate
renal impairment who are receiving dabigatran and keto-
conazole or dronedarone. Prescribing information for both
rivaroxaban and apixaban, which are both metabolized by
CYP3A4 and are P-gp substrates, indicate significant
interactions with ketoconazole, ritonavir, clarithromycin,
and erythromycin [30, 31]. Concomitant use of rivoraxaban
with drugs that are both P-gp inhibitors and strong
CYP3A4 inhibitors is to be avoided [30]. Patients receiving
apixaban should have their dose reduced when adminis-
tered along with a dual P-gp and strong CYP3A4 inhibitor
or avoid their concomitant use altogether [31].
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In conclusion, the results from this study indicate that
the PK of edoxaban in healthy subjects is increased by
coadministration of the potent P-gp inhibitors quinidine,
dronedarone, and verapamil. Concomitant administration
of each of these drugs with edoxaban significantly
increased exposure to edoxaban as reflected by either Cmax,
AUC, or 24-h concentrations relative to bleeding potential
predicted from modeling and simulation of exposure-
response relationships in patients with AF [14]. Atorva-
statin, digoxin, and amiodarone did not significantly affect
exposure to edoxaban. Coadministration of each tested
drug with edoxaban appeared to be well tolerated in these
short-term studies. The potential effects of coadministered
P-gp inhibitors on the clinical efficacy and safety of
edoxaban will be further evaluated in the large-scale phase
3 Hokusai-VTE and ENGAGE AF-TIMI 48 studies.
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